Physician profile
Natalie Inge Johnson
NPI 1356351977
$12,331.85
in general payments reported to CMS, 2019-2025
45 companies · $1,908 in 2025
The $1,908 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $634 · 2021: $1,102 · 2022: $2,310 · 2023: $2,958 · 2024: $2,941 · 2025: $1,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,717 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,717.04 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,518.70 | 2021-2025 | |
| Novo Nordisk INC | $1,232.78 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Next Science LLC | $917.71 | 2022-2025 | Blastx, Xperience, Surgx |
| Astrazeneca Pharmaceuticals LP | $855.80 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $823.07 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $787.71 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Misonix INC | $783.07 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $731.04 | 2021-2025 | |
| Astellas Pharma US INC | $620.23 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $616.63 | 2021-2025 | |
| Pfizer INC. | $473.16 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $330.32 | 2024-2025 | Rexulti |
| Amgen INC. | $247.96 | 2022-2025 | Repatha, Otezla, Repatha |
| Sumitomo Pharma America, INC. | $244.18 | 2023-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $231.00 | 2024-2025 | Voquezna |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $177.68 | 2022-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $169.00 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $148.44 | 2022-2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $146.41 | 2022-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.94 | 2022-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.44 | 2021-2025 | Xifaxan |
| Dexcom, INC. | $114.44 | 2022-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $99.87 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $90.76 | 2021-2024 | Xarelto |
| Tei Medical INC. | $87.42 | 2019 | |
| Solventum Corporation | $66.36 | 2024 | 3m Espe Filtek Supreme Ultra Universal Restorative, Activ.A.C. |
| Biohaven Pharmaceutical Holding Company LTD. | $65.28 | 2022 | |
| Smith+Nephew, INC. | $55.96 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $54.52 | 2022-2024 | Qelbree |
| Lundbeck LLC | $49.34 | 2024-2025 | Rexulti |
| Mylan Specialty L.P. | $48.53 | 2022-2023 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.62 | 2022-2025 | Caplyta |
| Corium, LLC | $33.50 | 2023 | Azstarys |
| Averitas Pharma INC. | $33.31 | 2025 | Qutenza |
| Convatec INC. | $25.87 | 2019 | |
| Horizon Therapeutics Plc | $25.01 | 2021 | |
| Paratek Pharmaceuticals, INC. | $19.74 | 2025 | Nuzyra |
| Xeris Pharmaceuticals, INC. | $19.11 | 2023 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $17.80 | 2025 | Symbravo |
| Bsn Medical INC | $17.47 | 2024 | |
| Dynavax Technologies Corporation | $16.53 | 2025 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $16.06 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.51 | 2023 | Seglentis, Livalo |
| Medline Industries LP | $12.58 | 2019 | |
| Organogenesis INC. | $10.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.